SCOOP: Tylenol Maker Privately Admitted Evidence Was Getting ‘Heavy’ For Autism Risk In 2018

(Worthy Insights) – The pharmaceutical company behind Tylenol privately acknowledged the likelihood of an association between its drug in pregnancy and neurodegenerative disorders like autism in children seven years ago, company documents obtained by the Daily Caller News Foundation show.

“The weight of the evidence is starting to feel heavy to me,” said Rachel Weinstein, U.S. director of epidemiology for Janssen, the pharmaceutical arm of Johnson & Johnson, in 2018. Johnson & Johnson marketed Tylenol at the time but in 2023 spun off its consumer products division into a separate company called Kenvue.

Legacy media headlines and vocal public health experts have dismissed the conclusion of President Donald Trump and Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. that Tylenol taken in pregnancy and early infancy has driven rises in autism. But one stakeholder has for years viewed the evidence as credible enough to act upon, at least privately: The makers of Tylenol. [ Source (Read More…) ]


Fair Use Notice:This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.

Leave a Comment